Haleon (LON:HLN) Price Target Raised to GBX 457 at Berenberg Bank

Haleon (LON:HLN - Get Free Report) had its price objective raised by research analysts at Berenberg Bank from GBX 456 ($5.88) to GBX 457 ($5.89) in a research note issued on Friday, February 28th,Digital Look reports. The firm presently has a "buy" rating on the stock. Berenberg Bank's target price indicates a potential upside of 14.42% from the company's previous close.

Haleon Trading Up 0.9 %

Shares of LON:HLN traded up GBX 3.70 ($0.05) during trading on Friday, reaching GBX 399.40 ($5.15). 11,079,927 shares of the company were exchanged, compared to its average volume of 26,231,000. The firm has a market capitalization of £36.05 billion, a PE ratio of 33.59, a P/E/G ratio of 1.49 and a beta of 0.19. The business's fifty day simple moving average is GBX 382.01 and its 200-day simple moving average is GBX 380.18. Haleon has a 12-month low of GBX 308.37 ($3.97) and a 12-month high of GBX 417.70 ($5.38). The company has a debt-to-equity ratio of 53.36, a current ratio of 0.84 and a quick ratio of 0.93.

Haleon (LON:HLN - Get Free Report) last issued its earnings results on Friday, February 28th. The company reported GBX 15.80 ($0.20) EPS for the quarter. Haleon had a return on equity of 6.54% and a net margin of 9.66%. On average, research analysts anticipate that Haleon will post 19.5033282 EPS for the current year.

Haleon Company Profile

Haleon LSE / NYSE: HLN is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges. Haleon's portfolio spans five global categories including Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health and Digestive Health and other.